{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:37:47Z","timestamp":1791049067680,"version":"4.1.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,11,6]],"date-time":"2007-11-06T00:00:00Z","timestamp":1194307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1186\/1750-1172-2-44","type":"journal-article","created":{"date-parts":[[2007,11,6]],"date-time":"2007-11-06T19:13:46Z","timestamp":1194376426000},"source":"Crossref","is-referenced-by-count":153,"title":["Myasthenia gravis"],"prefix":"10.1186","volume":"2","author":[{"given":"Vern C","family":"Juel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,11,6]]},"reference":[{"key":"95_CR1","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","volume":"126","author":"A Evoli","year":"2003","unstructured":"Evoli A, Tonali PA, Padua L, Lo Monaco M, Scuderi F, Batocchi AP, Marino M, Bartoccioni E: Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003, 126: 2304-2311. 10.1093\/brain\/awg223.","journal-title":"Brain"},{"key":"95_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A: Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001, 7: 365-368. 10.1038\/85520.","journal-title":"Nat Med"},{"key":"95_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ana.20061","volume":"55","author":"J McConville","year":"2004","unstructured":"McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A: Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004, 55: 580-584. 10.1002\/ana.20061.","journal-title":"Ann Neurol"},{"key":"95_CR4","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","volume":"60","author":"DB Sanders","year":"2003","unstructured":"Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A: Clinical aspects of MuSK antibody positive seronegative myasthenia gravis (SNMG). Neurology. 2003, 60: 1978-1980.","journal-title":"Neurology"},{"key":"95_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/01.LAB.0000028144.48023.9B","volume":"82","author":"F Scuderi","year":"2002","unstructured":"Scuderi F, Marino M, Colonna L, Mannella F, Evoli A, Provenzano C, Bartoccioni E: Anti-P110 autoantibodies identify a subtype of \"seronegative\" myasthenia gravis with prominent oculobulbar involvement. Lab Invest. 2002, 82: 1139-1146.","journal-title":"Lab Invest"},{"key":"95_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki III","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB: Myasthenia gravis: Recommendations for clinical research standards. Neurology. 2000, 55: 16-23.","journal-title":"Neurology"},{"key":"95_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1196\/annals.1254.053","volume":"998","author":"LH Phillips 2nd","year":"2003","unstructured":"Phillips LH: The epidemiology of myasthenia gravis. Ann NY Acad Sci. 2003, 998: 407-412. 10.1196\/annals.1254.053.","journal-title":"Ann NY Acad Sci"},{"key":"95_CR8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1212\/WNL.47.5.1233","volume":"47","author":"LH Phillips 2nd","year":"1996","unstructured":"Phillips LH, Torner JC: Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology. 1996, 47: 1233-1238.","journal-title":"Neurology"},{"key":"95_CR9","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1212\/01.WNL.0000050461.05432.C5","volume":"60","author":"JM Aragones","year":"2003","unstructured":"Aragones JM, Bolibar I, Bonfill X, Mummany A, Alonso F, Illa I: Myasthenia gravis. A higher than expected incidence in the elderly. Neurology. 2003, 60: 1024-1026. 10.1001\/archneur.60.7.1024-a.","journal-title":"Neurology"},{"key":"95_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jama.1953.02940230001001","volume":"153","author":"D Grob","year":"1953","unstructured":"Grob D: Course and management of myasthenia gravis. JAMA. 1953, 153: 529-532.","journal-title":"JAMA"},{"key":"95_CR11","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1749-6632.1981.tb33764.x","volume":"377","author":"D Grob","year":"1981","unstructured":"Grob D, Brunner NG, Namba T: The natural course of myasthenia gravis and effects of therapeutic measures. Ann NY Acad Sci. 1981, 377: 652-669. 10.1111\/j.1749-6632.1981.tb33764.x.","journal-title":"Ann NY Acad Sci"},{"key":"95_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1055\/s-2004-829591","volume":"24","author":"PI Andrews","year":"2004","unstructured":"Andrews PI: Autoimmune myasthenia gravis in childhood. Semin Neurol. 2004, 24: 101-110. 10.1055\/s-2004-829591.","journal-title":"Semin Neurol"},{"key":"95_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1212\/WNL.22.1.71","volume":"22","author":"T Santa","year":"1972","unstructured":"Santa T, Engel AG, Lambert EH: Histomeric study of neuromuscular junction ultrastructure I. Myasthenia gravis. Neurology. 1972, 22: 71-82.","journal-title":"Neurology"},{"key":"95_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/00005792-197809000-00002","volume":"57","author":"T Namba","year":"1978","unstructured":"Namba T, Brunner NG, Grob D: Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy. Medicine. 1978, 57: 411-433. 10.1097\/00005792-197809000-00002.","journal-title":"Medicine"},{"key":"95_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1055\/s-2008-1041255","volume":"10","author":"LH Phillips 2nd","year":"1990","unstructured":"Phillips LH, Melnick PA: Diagnosis of myasthenia gravis in the 1990s. Semin Neurol. 1990, 10: 62-69.","journal-title":"Semin Neurol"},{"key":"95_CR16","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1212\/WNL.39.6.865","volume":"39","author":"LY Dirr","year":"1989","unstructured":"Dirr LY, Donofrio PD, Patton JF, Troost BT: A false-positive edrophonium test in a patient with a brainstem glioma. Neurology. 1989, 39: 865-867.","journal-title":"Neurology"},{"key":"95_CR17","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1212\/WNL.39.9.1150","volume":"39","author":"G Moorthy","year":"1989","unstructured":"Moorthy G, Behrens MM, Drachman DB, Kirkham TH, Knox DL, Miller NR, Slamovitz TL, Zinreich SJ: Ocular pseudomyasthenia or ocular myasthenia \"plus\": A warning to clinicians. Neurology. 1989, 39: 1150-1154.","journal-title":"Neurology"},{"key":"95_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1212\/WNL.9.10.627","volume":"9","author":"DW Mulder","year":"1959","unstructured":"Mulder DW, Lambert EH, Eaton LM: Myasthenic syndrome in patients with ALS. Neurology. 1959, 9: 627-631.","journal-title":"Neurology"},{"key":"95_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1212\/WNL.42.4.917","volume":"42","author":"NK Ragge","year":"1992","unstructured":"Ragge NK, Hoyt WF: Midbrain myasthenia: fatigable ptosis, lid twitch sign, and ophthalmoparesis from a dorsal midbrain glioma. Neurology. 1992, 42: 917-919.","journal-title":"Neurology"},{"key":"95_CR20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0733-8619(18)30099-9","volume":"12","author":"JF Howard","year":"1994","unstructured":"Howard JF, Sanders DB, Massey JM: The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin. 1994, 12: 305-330.","journal-title":"Neurol Clin"},{"key":"95_CR21","volume-title":"Single fiber electromyography: studies in healthy and diseased muscle","author":"EV St\u00e5lberg","year":"1994","unstructured":"St\u00e5lberg EV, Trontelj JV: Single fiber electromyography: studies in healthy and diseased muscle 2nd edition. New York: Raven Press; 1994.","edition":"2"},{"key":"95_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mus.1139","volume":"24","author":"AAEM Quality Assurance Committee, American Association of Electrodiagnostic Medicine","year":"2001","unstructured":"AAEM Quality Assurance Committee, American Association of Electrodiagnostic Medicine: Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Summary statement. Muscle Nerve. 2001, 24: 1236-1238. 10.1002\/mus.1139.","journal-title":"Muscle Nerve"},{"key":"95_CR23","first-page":"1819","volume-title":"Neurology in clinical practice","author":"DB Sanders","year":"1991","unstructured":"Sanders DB, Howard JF: Disorders of neuromuscular transmission. Neurology in clinical practice. 1st edition. Edited by: Bradley WG, Daroff RB, Fenichel GM, Marsden CD. Boston: Butterworth-Heinemann; 1991:1819-1842.","edition":"1"},{"key":"95_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/0090-1229(77)90027-7","volume":"7","author":"J Lindstrom","year":"1977","unstructured":"Lindstrom J: An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol. 1977, 7: 36-43. 10.1016\/0090-1229(77)90027-7.","journal-title":"Clin Immunol Immunopathol"},{"key":"95_CR25","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","volume":"48","author":"A Vincent","year":"1985","unstructured":"Vincent A, Newsom-Davis J: Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 1985, 48: 1246-1252.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"95_CR26","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1212\/WNL.43.5.977","volume":"43","author":"PI Andrews","year":"1993","unstructured":"Andrews PI, Massey JM, Sanders DB: Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology. 1993, 43: 977-982.","journal-title":"Neurology"},{"key":"95_CR27","first-page":"149","volume-title":"Handbook of Myasthenia Gravis and Myasthenic Syndromes","author":"VA Lennon","year":"1994","unstructured":"Lennon VA: Serological diagnosis of myasthenia gravis and Lambert-Eaton myasthenic syndrome. Handbook of Myasthenia Gravis and Myasthenic Syndromes. Edited by: Lisak RP. New York: Marcel-Dekker; 1994:149-164."},{"issue":"Suppl 5","key":"95_CR28","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1212\/WNL.48.Suppl_5.40S","volume":"48","author":"DB Sanders","year":"1997","unstructured":"Sanders DB, Andrews I, Howard JF, Massey JM: Seronegative myasthenia gravis. Neurology. 1997, 48 (Suppl 5): S40-S45.","journal-title":"Neurology"},{"key":"95_CR29","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","volume":"505","author":"FM Howard Jr","year":"1987","unstructured":"Howard FM, Lennon VA, Finley J, Matsumoto J, Elveback LR: Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann NY Acad Sci. 1987, 505: 526-538. 10.1111\/j.1749-6632.1987.tb51321.x.","journal-title":"Ann NY Acad Sci"},{"key":"95_CR30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0025-6196(12)65645-6","volume":"63","author":"N Cikes","year":"1988","unstructured":"Cikes N, Momoi MY, Williams CL, Howard FM, Hoagland HC, Whittingham S, Lennon VA: Striational autoantibodies: Quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Mayo Clin Proc. 1988, 63: 474-481.","journal-title":"Mayo Clin Proc"},{"key":"95_CR31","doi-asserted-by":"publisher","first-page":"A229","DOI":"10.1159\/000066266","volume":"58","author":"DB Sanders","year":"2002","unstructured":"Sanders DB, Massey JM: The diagnostic utility of anti-striational antibodies in myasthenia gravis [abstract]. Neurology. 2002, 58: A229-10.1159\/000066266.","journal-title":"Neurology"},{"key":"95_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1212\/WNL.59.1.92","volume":"59","author":"FE Somnier","year":"2002","unstructured":"Somnier FE, Engel PJ: The occurrence of anti-titin antibodies and thymomas: A population survey of MG 1970\u20131999. Neurology. 2002, 59: 92-98.","journal-title":"Neurology"},{"key":"95_CR33","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/archneur.58.6.885","volume":"58","author":"AM Yamamoto","year":"2001","unstructured":"Yamamoto AM, Gajdos P, Eymard B, Tranchant C, Warter JM, Gomez L, Bourquin C, Bach JF, Garchon HJ: Anti-titin antibodies in myasthenia gravis. Tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol. 2001, 58: 885-890. 10.1001\/archneur.58.6.885.","journal-title":"Arch Neurol"},{"key":"95_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/jnnp.57.7.843","volume":"57","author":"A Mygland","year":"1994","unstructured":"Mygland A, Aarli JA, Matre R, Gilhus NE: Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry. 1994, 57: 843-846.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"95_CR35","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1212\/WNL.35.8.1219","volume":"35","author":"Y Chagnac","year":"1985","unstructured":"Chagnac Y, Hadanin M, Goldhammer Y: Myasthenic crisis after intravenous administration of iodinated contrast agent. Neurology. 1985, 35: 1219-1220.","journal-title":"Neurology"},{"key":"95_CR36","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S0140-6736(83)92749-6","volume":"1","author":"N Canal","year":"1983","unstructured":"Canal N, Franceschi M: Myasthenic crisis precipitated by iothalamic acid. Lancet. 1983, 1: 1288-10.1016\/S0140-6736(83)92749-6.","journal-title":"Lancet"},{"key":"95_CR37","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1212\/WNL.37.8.1400","volume":"37","author":"JH Frank","year":"1987","unstructured":"Frank JH, Cooper GW, Black WC, Phillips LH: Iodinated contrast agents in myasthenia gravis. Neurology. 1987, 37: 1400-1402.","journal-title":"Neurology"},{"key":"95_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11940-005-0001-7","volume":"7","author":"VC Juel","year":"2005","unstructured":"Juel VC, Massey JM: Autoimmune myasthenia gravis: Recommendations for treatment and immunologic modulation. Curr Treat Options Neurol. 2005, 7: 3-14. 10.1007\/s11940-005-0001-7.","journal-title":"Curr Treat Options Neurol"},{"key":"95_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0165-0173(96)00012-4","volume":"23","author":"BS McEwen","year":"1997","unstructured":"McEwen BS, Biron CA, Brunson KW, Bulloch K, Chambers WH, Dhabhar FS, Goldfarb RH, Kitson RP, Miller AH, Spencer RL, Weiss JM: The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Rev. 1997, 23: 79-133. 10.1016\/S0165-0173(96)00012-4.","journal-title":"Brain Res Rev"},{"key":"95_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Coslett HB, Johns TR: Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients. Ann Neurol. 1984, 15: 291-298. 10.1002\/ana.410150316.","journal-title":"Ann Neurol"},{"key":"95_CR41","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1749-6632.1987.tb51325.x","volume":"505","author":"TR Johns","year":"1987","unstructured":"Johns TR: Long-term corticosteroid treatment of myasthenia gravis. Ann NY Acad Sci. 1987, 505: 568-583. 10.1111\/j.1749-6632.1987.tb51325.x.","journal-title":"Ann NY Acad Sci"},{"key":"95_CR42","first-page":"CD002828","volume":"2","author":"C Schneider-Gold","year":"2005","unstructured":"Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR: Corticosteroids for myasthenia gravis. Cochrane Database of Systematic Reviews. 2005, 2: CD002828.","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"95_CR43","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1212\/WNL.36.5.729","volume":"36","author":"RG Miller","year":"1986","unstructured":"Miller RG, Milner-Brown HS, Mirka A: Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology. 1986, 36: 729-732.","journal-title":"Neurology"},{"key":"95_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1056\/NEJM197401102900204","volume":"290","author":"ME Seybold","year":"1974","unstructured":"Seybold ME, Drachman DB: Gradually increasing doses of prednisone in myasthenia gravis: reducing the hazards of treatment. N Engl J Med. 1974, 290: 81-84.","journal-title":"N Engl J Med"},{"key":"95_CR45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1212\/WNL.34.2.170","volume":"34","author":"A Sghirlanzoni","year":"1984","unstructured":"Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F: Myasthenia gravis: prolonged treatment with steroids. Neurology. 1984, 34: 170-174.","journal-title":"Neurology"},{"key":"95_CR46","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B: A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998, 50: 1778-1783.","journal-title":"Neurology"},{"key":"95_CR47","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/1531-8249(200005)47:5<682::AID-ANA24>3.0.CO;2-Z","volume":"47","author":"U Herrllinger","year":"2000","unstructured":"Herrllinger U, Weller M, Dichgans J, Melms A: Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis. Ann Neurol. 2000, 47: 682-683. 10.1002\/1531-8249(200005)47:5<682::AID-ANA24>3.0.CO;2-Z.","journal-title":"Ann Neurol"},{"key":"95_CR48","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1212\/WNL.38.2.258","volume":"38","author":"R Hohlfeld","year":"1988","unstructured":"Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV: Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology. 1988, 38: 258-261.","journal-title":"Neurology"},{"key":"95_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1212\/WNL.36.1.35","volume":"36","author":"JT Kissel","year":"1986","unstructured":"Kissel JT, Levy RJ, Mendell JR, Griggs RC: Azathioprine toxicity in neuromuscular disease. Neurology. 1986, 36: 35-39.","journal-title":"Neurology"},{"key":"95_CR50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","volume":"681","author":"RS Tindall","year":"1993","unstructured":"Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K: A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci. 1993, 681: 539-551. 10.1111\/j.1749-6632.1993.tb22937.x.","journal-title":"Ann NY Acad Sci"},{"key":"95_CR51","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/WNL.55.3.448","volume":"55","author":"E Ciafaloni","year":"2000","unstructured":"Ciafaloni E, Nikhar NK, Massey JM, Sanders DB: Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology. 2000, 55: 448-450.","journal-title":"Neurology"},{"key":"95_CR52","first-page":"2167","volume-title":"Neurology in clinical practice","author":"DB Sanders","year":"2000","unstructured":"Sanders DB, Howard JF: Disorders of neuromuscular transmission. Neurology in clinical practice. 3rd edition. Edited by: Bradley WG, Daroff RB, Fenichel GM, Marsden CD. Boston: Butterworth-Heinemann; 2000, 2167-2185.","edition":"3"},{"key":"95_CR53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","volume":"60","author":"HW Sollinger","year":"1995","unstructured":"Sollinger HW, Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995, 60: 225-232. 10.1097\/00007890-199508000-00003.","journal-title":"Transplantation"},{"key":"95_CR54","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/WNL.56.1.94","volume":"56","author":"V Chaudhry","year":"2001","unstructured":"Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB: Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases. Neurology. 2001, 56: 94-96.","journal-title":"Neurology"},{"key":"95_CR55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1212\/WNL.56.1.97","volume":"56","author":"E Ciafaloni","year":"2001","unstructured":"Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB: Mycophenolate mofetil for myasthenia gravis: An open-label pilot study. Neurology. 2001, 56: 97-99.","journal-title":"Neurology"},{"key":"95_CR56","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1196\/annals.1254.064","volume":"998","author":"MN Meriggioli","year":"2003","unstructured":"Meriggioli MN, Rowin J, Richman JG, Leurgans S: Mycophenolate mofetil for myasthenia gravis: A double-blind, placebo-controlled pilot study. Ann NY Acad Sci. 2003, 998: 494-499. 10.1196\/annals.1254.064.","journal-title":"Ann NY Acad Sci"},{"key":"95_CR57","doi-asserted-by":"publisher","first-page":"A107","DOI":"10.1159\/000110591","volume":"68","author":"D Sanders","year":"2007","unstructured":"Sanders D, McDermott M, Thornton C, Tawil A, Barohn R, the Muscle Study Group: A trial of mycophenolate mofetil (MMF) with prednisone as initial immunotherapy in myasthenia gravis (MG) [abstract]. Neurology. 2007, 68: A107-10.1159\/000110591.","journal-title":"Neurology"},{"key":"95_CR58","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1212\/01.wnl.0000173031.56429.04","volume":"65","author":"S Vernino","year":"2005","unstructured":"Vernino S, Salomao DR, Habermann TM, O'Neill BP: Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005, 65: 639-641. 10.1212\/01.wnl.0000173031.56429.04.","journal-title":"Neurology"},{"key":"95_CR59","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","volume":"61","author":"MN Meriggioli","year":"2003","unstructured":"Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB: Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003, 61: 1438-1440.","journal-title":"Neurology"},{"key":"95_CR60","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jama.1986.03380100107031","volume":"256","author":"NIH Consensus Conference","year":"1986","unstructured":"NIH Consensus Conference: The utility of therapeutic plasmapheresis for neurological disorders. JAMA. 1986, 256: 1333-1337. 10.1001\/jama.256.10.1333.","journal-title":"JAMA"},{"key":"95_CR61","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0140-6736(76)91917-6","volume":"2","author":"AF Pinching","year":"1976","unstructured":"Pinching AF, Peters DK, Newsom-Davis J: Remission of myasthenia gravis following plasma exchange. Lancet. 1976, 2: 1373-1376. 10.1016\/S0140-6736(76)91917-6.","journal-title":"Lancet"},{"key":"95_CR62","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJM197711242972102","volume":"297","author":"PC Dau","year":"1977","unstructured":"Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE: Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med. 1977, 297: 1134-1140.","journal-title":"N Engl J Med"},{"key":"95_CR63","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF00315690","volume":"238","author":"C Antozzi","year":"1991","unstructured":"Antozzi C, Gemma M, Regi B, Berta E, Confalonieri P, Peluchetti D, Mantegazza R, Baggi F, Marconi M, Fiacchino F, et al: A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol. 1991, 238: 103-107. 10.1007\/BF00315690.","journal-title":"J Neurol"},{"key":"95_CR64","first-page":"CD002275","volume":"4","author":"P Gajdos","year":"2002","unstructured":"Gajdos P, Chevret S, Toyka K: Plasma exchange for myasthenia gravis. Cochrane Database of Systematic Reviews. 2002, 4: CD002275.","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"95_CR65","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C: Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997, 41: 789-796. 10.1002\/ana.410410615.","journal-title":"Ann Neurol"},{"key":"95_CR66","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/WNL.52.3.629","volume":"52","author":"AI Qureshi","year":"1999","unstructured":"Qureshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, Ulatowski JA, Krendel DA, Leshner RT: Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999, 52: 629-632.","journal-title":"Neurology"},{"key":"95_CR67","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/archneur.1993.00540080046012","volume":"50","author":"RB Stricker","year":"1993","unstructured":"Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD: Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol. 1993, 50: 837-840.","journal-title":"Arch Neurol"},{"issue":"2","key":"95_CR68","first-page":"CD002277","volume":"19","author":"P Gajdos","year":"2006","unstructured":"Gajdos P, Chevret S, Toyka K: Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2006, 19 (2): CD002277.","journal-title":"Cochrane Database Syst Rev"},{"key":"95_CR69","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1034\/j.1600-0404.2003.00131.x","volume":"108","author":"C-S Huang","year":"2003","unstructured":"Huang C-S, Hsu H-S, Kao K-P, Huang M-H, Huang B-S: Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis. Acta Neurol Scand. 2003, 108: 136-138. 10.1034\/j.1600-0404.2003.00131.x.","journal-title":"Acta Neurol Scand"},{"key":"95_CR70","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","volume":"62","author":"P Gajdos","year":"2005","unstructured":"Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, Attarian S, Chevret S, Myasthenia Gravis Clinical Study Group: Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin 1g\/kg versus 2g\/kg: A randomized double blind clinical trial. Ann Neurol. 2005, 62: 1689-1693. 10.1001\/archneur.62.11.1689.","journal-title":"Ann Neurol"},{"key":"95_CR71","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/archneur.1993.00540020015010","volume":"50","author":"E Tan","year":"1993","unstructured":"Tan E, Hajinazarian M, Bay W, Neff J, Mendel JR: Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol. 1993, 50: 137-139.","journal-title":"Arch Neurol"},{"key":"95_CR72","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1212\/01.WNL.0000068335.01620.9D","volume":"60","author":"JB Caress","year":"2003","unstructured":"Caress JB, Cartwright MS, Donofrio PD, Peacock JE: The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003, 60: 1822-1824.","journal-title":"Neurology"},{"key":"95_CR73","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jama.1941.02820440037009","volume":"117","author":"A Blalock","year":"1941","unstructured":"Blalock A, Harvey AM, Ford FR, Lilienthal JL: The treatment of myasthenia gravis by removal of the thymus gland. J American Medical Association. 1941, 117: 1529-1533.","journal-title":"J American Medical Association"},{"key":"95_CR74","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0096-5588(20)31647-0","volume":"13","author":"A Blalock","year":"1944","unstructured":"Blalock A: Thymectomy in the treatment of myasthenia gravis. Report of twenty cases. J Thorac Surg. 1944, 13: 316-339.","journal-title":"J Thorac Surg"},{"key":"95_CR75","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1196\/annals.1254.061","volume":"998","author":"GI Wolfe","year":"2003","unstructured":"Wolfe GI, Kaminski HJ, Jaretzki A, Swan A, Newsom-Davis J: Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann NY Acad Sci. 2003, 998: 473-480. 10.1196\/annals.1254.061.","journal-title":"Ann NY Acad Sci"},{"key":"95_CR76","unstructured":"A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone (MGTX). Accessed 15 March 2007, [ http:\/\/www.soph.uab.edu\/mgtx\/ ]"},{"key":"95_CR77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1212\/WNL.55.1.7","volume":"55","author":"GS Gronseth","year":"2000","unstructured":"Gronseth GS, Barohn RJ: Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000, 55: 7-15.","journal-title":"Neurology"},{"key":"95_CR78","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1749-6632.1971.tb30761.x","volume":"183","author":"VP Perlo","year":"1971","unstructured":"Perlo VP, Arnason B, Poskanzer D, Castleman B, Schwab RS, Osserman KE, Papatestis A, Alpert L, Kark A: The role of thymectomy in the treatment of myasthenia gravis. Ann NY Acad Sci. 1971, 183: 308-315. 10.1111\/j.1749-6632.1971.tb30761.x.","journal-title":"Ann NY Acad Sci"},{"key":"95_CR79","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/ana.410130506","volume":"13","author":"M Rodriguez","year":"1983","unstructured":"Rodriguez M, Gomez MR, Howard FM, Taylor WF: Myasthenia gravis in children: Long-term follow-up. Ann Neurol. 1983, 13: 504-510. 10.1002\/ana.410130506.","journal-title":"Ann Neurol"},{"key":"95_CR80","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0003-4975(10)66861-0","volume":"48","author":"DG Mulder","year":"1989","unstructured":"Mulder DG, Graves M, Hermann C: Thymectomy for myasthenia gravis: Recent observation and comparisons with past experience. Ann Thorac Surg. 1989, 48: 551-555.","journal-title":"Ann Thorac Surg"},{"key":"95_CR81","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0003-4975(10)62253-9","volume":"38","author":"Y Monden","year":"1984","unstructured":"Monden Y, Nakahara K, Kagotani K, Fujii Y, Nanjo S, Masaoka A, Kawashima Y: Effects of preoperative duration of symptoms on patients with myasthenia gravis. Ann Thorac Surg. 1984, 38: 287-291.","journal-title":"Ann Thorac Surg"},{"key":"95_CR82","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0022-510X(91)90260-E","volume":"106","author":"E Beghi","year":"1991","unstructured":"Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, Lombardi M, Mantegazza R, Monticelli ML, Piccolo G, et al: Prognosis of myasthenia gravis: A multicenter follow-up study of 844 patients. J Neurol Sci. 1991, 106: 213-220. 10.1016\/0022-510X(91)90260-E.","journal-title":"J Neurol Sci"},{"key":"95_CR83","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1212\/WNL.40.12.1828","volume":"40","author":"DJ Lanska","year":"1990","unstructured":"Lanska DJ: Indications for thymectomy in myasthenia gravis. Neurology. 1990, 40: 1828-1829.","journal-title":"Neurology"},{"key":"95_CR84","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/jnnp.48.4.332","volume":"48","author":"F Schumm","year":"1985","unstructured":"Schumm F, Wietholter H, Fateh-Moghadam A, Dichgans J: Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry. 1985, 48: 332-337.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 5","key":"95_CR85","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1212\/WNL.48.Suppl_5.52S","volume":"48","author":"A Jaretzki III","year":"1997","unstructured":"Jaretzki A: Thymectomy for myasthenia gravis: Analysis of the controversies regarding technique and results. Neurology. 1997, 48 (Suppl 5): S52-S63.","journal-title":"Neurology"},{"key":"95_CR86","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1055\/s-2004-829596","volume":"24","author":"A Jaretzki III","year":"2004","unstructured":"Jaretzki A, Steinglass KM, Sonett JR: Thymectomy in the management of myasthenia gravis. Semin Neurol. 2004, 24: 49-62. 10.1055\/s-2004-829596.","journal-title":"Semin Neurol"},{"key":"95_CR87","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0003-4975(02)03811-0","volume":"75","author":"A Jaretzki III","year":"2003","unstructured":"Jaretzki A, Aarli JA, Kaminski HJ, Phillips LH, Sanders DB: Preoperative preparation of patients with myasthenia gravis forestalls postoperative respiratory complications after thymectomy. Ann Thorac Surg. 2003, 75: 1068-10.1016\/S0003-4975(02)03811-0.","journal-title":"Ann Thorac Surg"},{"key":"95_CR88","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00000658-199709000-00012","volume":"226","author":"GB Bulkley","year":"1997","unstructured":"Bulkley GB, Bass KN, Stephenson GR, Diener-West M, George S, Reilly PA, Baker RR, Drachman DB: Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis. Ann Surg. 1997, 226: 324-334. 10.1097\/00000658-199709000-00012.","journal-title":"Ann Surg"},{"key":"95_CR89","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","volume":"52","author":"HJ Oosterhuis","year":"1989","unstructured":"Oosterhuis HJ: The natural course of myasthenia gravis: A long-term followup study. J Neurol Neurosurg Psychiatry. 1989, 52: 1121-1127.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"95_CR90","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1097\/00007611-198510000-00017","volume":"78","author":"MS Sellman","year":"1985","unstructured":"Sellman MS, Mayer RF: Treatment of myasthenic crisis in late life. South Med J. 1985, 78: 1208-1210.","journal-title":"South Med J"},{"key":"95_CR91","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","volume":"48","author":"CE Thomas","year":"1997","unstructured":"Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, Brannagan TH, Fink ME, Rowland LP: Myasthenic crisis: Clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997, 48: 1253-1260.","journal-title":"Neurology"},{"key":"95_CR92","unstructured":"Pascuzzzi RM: Medications and myasthenia gravis: A reference for health care professionals. Accessed 15 March 2007, [ http:\/\/myasthenia.org\/docs\/MGFA_MedicationsandMG.pdf ]"},{"key":"95_CR93","first-page":"78","volume-title":"Myasthenia gravis","author":"KE Osserman","year":"1958","unstructured":"Osserman KE: Myasthenia gravis. New York: Grune & Stratton; 1958:78-80."},{"key":"95_CR94","first-page":"693","volume":"64","author":"JA Simpson","year":"1987","unstructured":"Simpson JA, Thomaides T: Treatment of myasthenia gravis: An audit. Q J Med. 1987, 64: 693-704.","journal-title":"Q J Med"},{"key":"95_CR95","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oso\/9780195129700.003.0006","volume-title":"Myasthenia gravis and myasthenic disorders","author":"D Grob","year":"1999","unstructured":"Grob D: Natural history of myasthenia gravis. Myasthenia gravis and myasthenic disorders. Edited by: Engel AG. 1999, New York: Oxford University Press, 131-154."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1750-1172-2-44.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1750-1172-2-44\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1750-1172-2-44.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T21:49:07Z","timestamp":1708292947000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/1750-1172-2-44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,6]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["95"],"URL":"https:\/\/doi.org\/10.1186\/1750-1172-2-44","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,6]]},"article-number":"44"}}